1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,662 | 1,742 | 08:41 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| MOLECURE Aktie jetzt für 0€ handeln | |||||
| 28.03.25 | Strategic update on the progress and development of Molecure's key clinical projects in 2024 | 360 | GlobeNewswire (Europe) | Molecure achieved key milestones in the development of its innovative therapies in 2024 and plans to accelerate research and development in its most advanced clinical programs: OATD-01 and OATD-02.... ► Artikel lesen |
1 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CO.DON | 0,014 | -22,86 % | EQS-AFR: CO.DON AG i.l.: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: CO.DON AG i.l.
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
CO.DON AG i.l.: Vorabbekanntmachung über die... ► Artikel lesen | |
| SANGAMO THERAPEUTICS | 0,351 | +4,49 % | Weekly Buzz: ATYR To Meet With FDA, SGMO Aces Fabry Study, AQST's Anaphylm Gets Rejected | PETAH TIKVA (dpa-AFX) - This week's biotech landscape witnessed key FDA meetings being scheduled, IND clearances, complete response letters, sale of oncology assets and clinical trial data readouts... ► Artikel lesen | |
| IMMATICS | 8,295 | -2,01 % | Immatics Presents IMA203CD8 PRAME Cell Therapy Data from Ongoing Dose Escalation and Shows Promising Initial Anti-tumor Activity in PRAME-Positive Tumors at ESMO-IO 2025 Congress | IMA203CD8 is a second-generation PRAME cell therapy with enhanced pharmacology in ongoing Phase 1a dose escalationManageable tolerability across all dose levelsEncouraging early clinical anti-tumor... ► Artikel lesen | |
| ALDEYRA | 4,446 | +1,16 % | Aldeyra Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | ||
| MEDIFAST | 8,786 | -2,38 % | Medifast: OPTAVIA Premieres Second Docuseries Episode "Health by Design: Spain" Exploring Metabolic Health and Longevity | Thousands of Independent Coaches Gather Nationwide to Discuss Solutions to America's Metabolic Health Crisis Medifast (NYSE: MED), the health and wellness company known for its science-backed... ► Artikel lesen | |
| PHARMING | 1,339 | -1,40 % | Pharming Group N.V.: Pharming Group to report fourth quarter and full year 2025 financial results and provide business update on March 12 | Leiden, the Netherlands, February 26, 2026: Pharming Group N.V. ("Pharming" or "the Company") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms that it will report its preliminary (unaudited) financial... ► Artikel lesen | |
| COHERUS ONCOLOGY | 1,391 | -2,35 % | Coherus Oncology, Inc.: Coherus Oncology to Report Full Year and Fourth Quarter 2025 Financial Results on March 9, 2026 | ||
| ORUKA THERAPEUTICS | 28,800 | +2,13 % | Oruka Therapeutics, Inc.: Oruka Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update | ORKA-001 Phase 1 results presented at EADV show potential for once-per-year dosing, higher efficacy and off-treatment remission Over $500M cash and equivalents provides runway over one year past three... ► Artikel lesen | |
| INNOVIVA | 19,300 | 0,00 % | Innoviva: EPS übertrifft Schätzungen um 1,37 $ - Umsatz besser als erwartet | ||
| ARMATA PHARMACEUTICALS | 9,850 | +1,55 % | Armata Pharmaceuticals, Inc.: Armata Pharmaceuticals Receives FDA Qualified Infectious Disease Product (QIDP) Designation for AP-SA02 | Intravenous use as a QIDP for adjunct treatment of complicated bacteremia caused by Staphylococcus aureus
QIDP Designation provides for five years of market exclusivity... ► Artikel lesen | |
| DBV TECHNOLOGIES | 3,770 | 0,00 % | DBV Technologies S.A.: Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of February 28, 2026 | Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of February 28, 2026
(Article 223-16 of the General Regulations of the Autorité des Marchés Financiers)
Market... ► Artikel lesen | |
| BRAINSTORM CELL THERAPEUTICS | 0,673 | -100,00 % | BrainStorm Cell Therapeutics Inc.: Brainstorm Cell Therapeutics Secures Second $1 Million Strategic Placement; Total $2 Million Raised In February | NEW YORK, Feb. 26, 2026 /PRNewswire/ -- Brainstorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapies for neurodegenerative... ► Artikel lesen | |
| SYNDAX PHARMACEUTICALS | 18,600 | +1,09 % | Syndax Pharmaceuticals, Inc.: Syndax Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update | - Total revenue of $68.7 million in 4Q25 and $172.4 million in FY2025 - - Revuforj- (revumenib) net revenue of $44.2 million in 4Q25, a 38% increase vs 3Q25, and $124.8 million in FY2025 - - Niktimvo... ► Artikel lesen | |
| SIGA TECHNOLOGIES | 6,545 | 0,00 % | SIGA Technologies Inc.: SIGA to Host Business Update Call on March 10, 2026, Following Release of 2025 Financial Results | ||
| LIQUIDIA | 27,240 | +3,73 % | MannKind, Liquidia fall as United Therapeutics mulls new treprostinil formulation |
MOLECURE SA gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,074 (-4,24 %) liegt der Kurs bei 1,670 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MOLECURE SA finden Sie auf Wallstreet Online.